List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4693949/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	27.0	1,752

 $_{2}$ Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and) Tj ETQq0 $_{13.7}^{0.0}$ rgBT /Overlock 10

3	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of	1.9	690
<u> </u>	Dermatological Research, 2011, 303, 1-10.	1.9	- 090-
4	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. New England Journal of Medicine, 2012, 366, 1859-1869.	27.0	511
5	European S3â€Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp> . Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	2.4	353
6	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet, The, 2015, 386, 552-561.	13.7	350
7	Guidelines on the use of extracorporeal photopheresis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1-37.	2.4	212
8	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European Journal of Cancer, 2017, 86, 334-348.	2.8	212
9	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 742-750.	5.7	211
10	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. British Journal of Dermatology, 2017, 176, 928-938.	1.5	155
11	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. European Journal of Cancer, 2020, 126, 159-177.	2.8	154
12	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. European Journal of Cancer, 2020, 126, 141-158.	2.8	133
13	ï‰-3 Fatty acid–based lipid infusion in patients with chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, multicenter trial. Journal of the American Academy of Dermatology, 1998, 38, 539-547.	1.2	128
14	Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, The, 2014, 384, 2036-2045.	13.7	124
15	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). European Journal of Cancer, 2019, 114, 117-127.	2.8	120
16	Interleukin-8 receptor-mediated chemotaxis of normal human epidermal cells. FEBS Letters, 1992, 305, 241-243.	2.8	104
17	Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. pallidum. Journal of Medical Microbiology, 2009, 58, 832-836.	1.8	104
18	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. European Journal of Cancer, 2022, 170, 236-255.	2.8	102

#	Article	IF	CITATIONS
19	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. British Journal of Dermatology, 2010, 163, 402-411.	1.5	99
20	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32â€week results from the randomized placebo ontrolled <scp>TRANSFIGURE</scp> trial. British Journal of Dermatology, 2019, 181, 954-966.	1.5	84
21	Multiple switches between <scp>CP</scp> 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaqueâ€type psoriasis: 30â€week results from the phase 3, confirmatory <scp>EGALITY</scp> study. Journal of the European Academy of Dermatology and Venereology. 2018. 32, 420-427.	2.4	70
22	Acute bronchitis therapy with ivy leaves extracts in a two-arm study. A double-blind, randomised study vs. an other ivy leaves extract. Phytomedicine, 2011, 18, 1105-1109.	5.3	60
23	Lightâ€activated nanofibre textiles exert antibacterial effects in the setting of chronic wound healing. Experimental Dermatology, 2012, 21, 619-624.	2.9	60
24	Towards optimization of an organotypic assay system that imitates human hair follicle-like epithelial-mesenchymal interactions. British Journal of Dermatology, 2004, 151, 753-765.	1.5	56
25	Photodynamic Therapy of Necrobiosis Lipoidica – A Multicenter Study of 18 Patients. Dermatology, 2009, 218, 136-139.	2.1	55
26	Quality of Life in Patients with Uraemic Xerosis and Pruritus. Acta Dermato-Venereologica, 2011, 91, 313-317.	1.3	53
27	European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2693-2716.	2.4	49
28	Effective longâ€ŧerm control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. International Journal of Dermatology, 2010, 49, 1445-1449.	1.0	46
29	Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2222-2230.	2.4	41
30	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5â€year results from the randomized placeboâ€controlled TRANSFIGURE study*. British Journal of Dermatology, 2021, 184, 425-436.	1.5	36
31	Gene expression in actinic keratoses: pharmacological modulation by imiquimod. British Journal of Dermatology, 2004, 151, 1150-1159.	1.5	33
32	Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic. Dermatology and Therapy, 2021, 11, 1345-1355.	3.0	29
33	European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 27-49.	2.4	28
34	New and current preventive treatment options in actinic keratosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 13-17.	2.4	25
35	Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study. Journal of Dermatology, 2017, 44, 363-369.	1.2	25
36	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. Cerebrovascular Diseases, 2014, 38, 176-181.	1.7	24

#	Article	IF	CITATIONS
37	Phase 3 evaluation of HP802â€⊉47 in the treatment of chronic venous leg ulcers. Wound Repair and Regeneration, 2016, 24, 894-903.	3.0	24
38	The evolving field of Dermatoâ€oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22
39	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. Circulation: Heart Failure, 2015, 8, 504-509.	3.9	21
40	Confocal laser-scanning capillaroscopy: a novel approach to the analysis of skin capillariesin vivo. Skin Research and Technology, 2009, 15, 476-481.	1.6	20
41	Characteristics and risk profile of psoriasis patients included in the Czech national registry <scp>BIOREP</scp> and a comparison with other registries. International Journal of Dermatology, 2017, 56, 428-434.	1.0	18
42	Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after antiâ€TNF failure. International Journal of Dermatology, 2020, 59, 733-735.	1.0	17
43	Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of antiâ€ŧumour necrosis factor alpha. British Journal of Dermatology, 2021, 184, 966-967.	1.5	17
44	Langerhans cells of the human skin possess high-affinity 12(S)-hydroxyeicosa tetraenoic acid receptors. European Journal of Immunology, 1992, 22, 2469-2472.	2.9	16
45	Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. Journal of the European Academy of Dermatology and Venereology, 2007, 22, 070806223155002-???.	2.4	16
46	Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e253-e254.	2.4	16
47	Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. JDDG - Journal of the German Society of Dermatology, 2019, 17, 698-702.	0.8	16
48	Regulation of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) binding sites on human epidermal cells by interferon-γ. Experimental Cell Research, 1990, 191, 204-208.	2.6	15
49	Effect of topical heparin and levomenol on atopic dermatitis: a randomized fourâ€arm, placeboâ€controlled, doubleâ€blind clinical study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 688-694.	2.4	15
50	Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. Journal of Dermatological Treatment, 2021, 32, 164-173.	2.2	15
51	Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line. Archives of Dermatological Research, 1991, 283, 333-336.	1.9	14
52	Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study. Current Therapeutic Research, 2018, 88, 1-7.	1.2	14
53	Quantitative detection of melanomaâ€associated antigens by multimarker realâ€time RTâ€PCR for molecular staging: results of a 5 years study. Experimental Dermatology, 2010, 19, 994-999.	2.9	13
54	Successful radiotherapy of facial angiosarcoma. International Journal of Dermatology, 2008, 47, 1190-1192.	1.0	12

#	Article	IF	CITATIONS
55	Defect of epidermal 12(S)-hydroxyeicosatetraenoic acid receptors in psoriasis. European Journal of Clinical Investigation, 1992, 22, 235-243.	3.4	11
56	Substance P binding in normal neonatal foreskin. British Journal of Dermatology, 1995, 132, 54-58.	1.5	10
57	Incidence of cutaneous malignant melanoma in the Czech Republic: The risks of sun exposure for adolescents. Neoplasma, 2012, 59, 316-325.	1.6	10
58	A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2063-2064.	2.4	10
59	The HLA-Cw*06 allele and â^1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population. Rheumatology International, 2013, 33, 913-919.	3.0	9
60	FRI0460â€Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. Annals of the Rheumatic Diseases, 2016, 75, 603.2-604.	0.9	9
61	Melanoma antigens are biomarkers for ipilimumab response. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 252-259.	2.4	9
62	Increased sensitivity and high specificity of indirect immunofluorescence in detecting IgG subclasses for diagnosis of bullous pemphigoid. Clinical and Experimental Dermatology, 2018, 43, 248-253.	1.3	9
63	Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sexâ€specific differences in psoriasis in the Czech Republic. Dermatologic Therapy, 2021, 34, e14849.	1.7	9
64	Malignant melanoma in the Czech Republic: Incidence and mortality according to sex, age and disease stage. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2014, 158, 438-446.	0.6	9
65	Management of psoriasis vulgaris and multiple sclerosis with fumaric acid. Journal of the American Academy of Dermatology, 2014, 70, e60-e61.	1.2	8
66	Expected outcomes from topical haemoglobin spray in non-healing and worsening venous leg ulcers. Journal of Wound Care, 2015, 24, 228-236.	1.2	8
67	Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. Dermatologic Therapy, 2017, 30, e12522.	1.7	8
68	Dead Sea ultraviolet climatotherapy for children with atopic dermatitis. Photodermatology Photoimmunology and Photomedicine, 2016, 32, 254-261.	1.5	7
69	The Lipoxygenase Inhibitor 2-Phenylmethyl-1-Naphthol (DuP 654) Is a 12(S)-Hydroxyeicosatetraenoic Acid Receptor Antagonist in the Human Epidermal Cell Line SCL-II. Skin Pharmacology and Physiology, 1993, 6, 148-151.	2.5	6
70	Scalp melanoma after antihair loss mesotherapy. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e187-e188.	2.4	6
71	Training requirements and recommendation for the specialty of dermatology and venereology <i>European Standards of Postgraduate Medical Specialist Training</i> . Journal of the European Academy of Dermatology and Venereology, 2019, 33, 3-25.	2.4	6
72	Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e281-e283.	2.4	6

#	Article	IF	CITATIONS
73	Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic. Dermatology and Therapy, 2021, 11, 543-553.	3.0	6
74	Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 562-568.	0.6	6
75	Effect of Ciclosporin on Epidermal 12(S)-Hydroxyeicosatetraenoic Acid Binding Sites. Skin Pharmacology and Physiology, 1991, 4, 272-277.	2.5	5
76	Inhibition of 12(S)-Hydroxyeicosatetraenoic Acid [12(S)-HETE] Binding to Epidermal Cells by Ultraviolet-B. Journal of Investigative Dermatology, 1991, 97, 1028-1031.	0.7	5
77	Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. Journal of Dermatological Treatment, 2018, 29, 579-582.	2.2	5
78	Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and Bâ€cell chronic lymphocytic leukaemia. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e72-e74.	2.4	5
79	Longâ€ŧerm impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study. Dermatologic Therapy, 2020, 33, e14110.	1.7	5
80	The treatment of unilesional mycosis fungoides with methyl aminolevulinateâ€photodynamic therapy. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1134-1135.	2.4	4
81	New developments in fluorescence diagnostics. JDDG - Journal of the German Society of Dermatology, 2011, 9, 368-372.	0.8	4
82	Dead Sea climatotherapy versus topical steroid treatment for atopic dermatitis children: long-term follow-up study. Journal of Dermatological Treatment, 2020, 31, 711-715.	2.2	4
83	Palladium causes bizarre skin hyperpigmentation in longâ€ŧerm dihydrocodeinone â€~Braun' abusers. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 188-191.	2.4	4
84	Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e381-e383.	2.4	4
85	Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab. British Journal of Dermatology, 2021, 184, e195.	1.5	4
86	Severe diclofenac photoallergy in a patient treated with vemurafenib. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 713-715.	2.4	3
87	Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1626-1627.	2.4	3
88	Severe exacerbation of psoriasis after intravenous immunoglobulin in patient with multiple sclerosis that started during biologic therapy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 355-356.	2.4	3
89	Acrodermatitis continua Hallopeau successfully treated by risankizumab. International Journal of Dermatology, 2021, 60, e144-e145.	1.0	3
90	Temporal arteritis with scalp ulceration and blindness. JDDG - Journal of the German Society of Dermatology, 2011, 9, 50-52.	0.8	2

#	Article	IF	CITATIONS
91	Targeted treatment of metastatic melanoma in a drugâ€addicted patient with preâ€existing hepatitis C. Dermatologic Therapy, 2019, 32, e12790.	1.7	2
92	COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma. Journal of Dermatological Treatment, 2022, 33, 1782-1783.	2.2	2
93	Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab. Dermatologic Therapy, 2021, 34, e14708.	1.7	2
94	Urinary Tract Desquamation in Psoriasis. Dermatology, 1990, 180, 112-112.	2.1	1
95	Neue Entwicklungen in der Fluoreszenzdiagnostik. JDDG - Journal of the German Society of Dermatology, 2011, 9, 368-373.	0.8	1
96	Longâ€ŧerm combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis <scp>D</scp> uhring. Journal of Dermatology, 2012, 39, 0-0.	1.2	1
97	Quantitative changes of melanomaâ€associated antigens as a biomarker for targeted therapy response. Experimental Dermatology, 2016, 25, 727-729.	2.9	1
98	Deroofing mit anschließender sorgfÃæiger Sinustraktâ€Exzision: ein modifizierter chirurgischer Ansatz bei Hidradenitis suppurativa. JDDG - Journal of the German Society of Dermatology, 2019, 17, 698-702.	0.8	1
99	Alopecia barbae severity score: A novel scoring system to estimate the extent of beard loss and success of treatment. British Journal of Dermatology, 2021, 185, 847-849.	1.5	1
100	Current therapeutical options in primary cutaneous T-cell lymphomas. Dermatologie Pro Praxi, 2018, 12, 31-35.	0.0	1
101	Characterization of high-affinity 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) binding sites on normal human keratinocytes. Epithelial Cell Biology, 1993, 2, 1-6.	0.1	1
102	Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic. Central European Journal of Public Health, 2022, 30, 46-50.	1.1	1
103	Interleukin-8 receptors in normal and psoriatic polymorphonuclear leukocytes. Acta Dermato-Venereologica, 1992, 72, 334-6.	1.3	1
104	Eruptive multiple Spitz nevi in a patient with epilepsy and drug addiction. JDDG - Journal of the German Society of Dermatology, 2011, , no-no.	0.8	0
105	JDDG - the first English print version. JDDG - Journal of the German Society of Dermatology, 2013, 11, 278a-278b.	0.8	Ο
106	The role of the dermatologist in the immuneâ€mediated/allergic diseases – position statement of the EADV task force on contact dermatitis, EADV task force on occupational skin diseases, UEMSâ€EBDV subcommission allergology and European Dermatology Forum. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1459-1464.	2.4	0
107	Darier disease complicated by severe Kaposi varicelliform eruption resistant to acyclovir. Dermatologic Therapy, 2020, 33, e14500.	1.7	Ο
108	Answer to the comment by Plachouri <i>et al</i> . on the necessity for adequate training of European dermatology residents in skin of colour. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e597-e598.	2.4	0

#	Article	IF	CITATIONS
109	Unusual periungual nodulocystic lesions leading to the diagnosis of extranodal marginal zone lymphoma. Indian Journal of Dermatology, 2020, 65, 83.	0.3	0
110	Cultivation of psoriatic keratinocytes and an attempt to isolate and detect a specific psoriatic antigen. Folia Biologica, 1991, 37, 52-4.	0.6	0
111	Tissue-engineered skin in the treatment of vitiligo lesions. Folia Biologica, 2000, 46, 157-60.	0.6	0